Greg Raines: Senate Candidate Profiles

Federal Election 2013: Victorian Candidate

Greg Raines is an Australian Democrats Senate Candidate for Victoria and a passionate voice for stronger accountability in the Federal parliament. Greg came to the Australian Democrats because it was the only party with policies that care for people, the environment and sound economic principle. Since taking up an active role in politics Greg has worked passionately on issues including mental health, workplace relations, migrant rights, economic sustainability, law reform and protecting Australia’s precious biotechnology and medical research industry.

An Australian Democrats spokesperson on Workplace Relations and Biotechnology, Greg will lead opposition in Canberra against attempts to water down our employment laws, while also protecting Australia’s high value biotechnology industry. With a background working in forensic audit, health economics and employment law, Greg has brought a strong compliance and accountability focus to the Australian Democrats team contesting this election.

Greg has been a leading voice against the attempts of supermarket giants Coles and Woolworths to be permitted to open pharmacies within their stores. Besides the initial cost saving argument similarly used for their ‘supermarket petrol model’, there are very serious compelling reasons why supermarkets should not be involved in the health market. Forecasting shows very little cost saving along term for the consumer, while the add-on impact to our biotech and medical research industry will be devastating as the supermarket giants wield their power on such a significant industry to Australia’s continued prosperity.

Greg believes that biotechnology and medical research is a key industry that Australia must focus on for continued economic growth as we move away from reliance on our mining sector. To capitalise on this unique opportunity, we need well designed policies that encourage the full economic benefits of this high value industry, from basic research and development (R&D) to full scale manufacturing.

Greg has also backed diverse initiatives to ensure better opportunities and protections for migrant and indigenous Australians in the workplace. He is particularly proud of the human rights work he has performed overseas and is an advocate for treating refugees with compassion and for respecting our international legal obligations.

Greg grew up in Melbourne, attended Monash University, and is currently Managing Director at Thornton Tucker & Associates, continuing his commitment to ‘Employment Justice for all Australians’. His professional emphasis is on human rights, combating discrimination and protecting employee rights.

2017-01-13T13:05:12+00:00 Tags: , , |

2 Comments

  1. Greg Raines February 23, 2017 at 3:02 am - Reply

    Protecting Australia’s high value biotechnology industry:

    It seems a flitter in the pulse of the mining sector due to a short term strengthening of commodity and metal prices is enough for the federal government to consider a cap on existing tax incentives for small and start up biotech companies that would be forced into foreign hands should they be limited to a $2 million dollar R&D cap…

    The R&D Tax Incentive Review paper was released on 28th of September, making recommendations on changes to the scheme – including a proposed $2Million cap on the annual cash refund payable under the R&D Tax Incentive. The proposed changes will need to be analysed to assess their full impact on the sector – but it is clear that biotech and medtech companies will be affected by the proposed refundable cap which places a ceiling on the level of innovation support for high-growth potential companies.

    Preliminary analysis indicates that in the biotech sector the R&D tax incentive was fulfilling policy objectives, in terms of driving additional and effective R&D activity and delivering strong economic outcomes in terms of jobs and growth. Of the small data set we have complied to date – more than 40% of biotech companies will be impacted by this proposed $2Million R&D tax incentive cap.

  2. Greg Raines March 30, 2017 at 9:04 am - Reply

    Pharmacy in supermarkets:

    In what can only highlight the risks and lack of any real understanding around health care, supermarkets are already loading their shelves with potentially dangerous over the counter drugs. Medications such as ibuprofen and aspirin, are widely available over the counter in supermarkets. But health providers have known for some time they can be unsafe for people with chronic health problems such as kidney disease, high blood pressure or heart failure. These drugs can have dangerous interactions with other commonly taken medications, notably many types of blood pressure and blood-thinning pills such as warfarin and aspirin. Two recently published studies have brought back into the spotlight the possible heart-related side effects. One found an increased risk of heart failure, while another an increased risk of cardiac arrest.

    The recent studies are an important reminder that over-the-counter medicines are not without risk. Woolworths and Coles supermarkets were unavailable for comment when asked if they would demonstrate the same inert standards if they were allowed a pharmacy licence.

    News Greg Raines

Leave A Comment